Treatment strategies aimed at improving the microenvironment around hair follicles
Treatment strategies aimed at improving the microenvironment around hair follicles
Data from the "White Paper on Chinese Scalp Health" shows that the number of hair loss in China has exceeded 250 million, with an average of 1 in 6 people losing hair
The good news is that a new achievement is expected to free people from hair loss
Related research results have been published on ACS Nano
ACS Nano Androgen-induced alopecia is the most common
Androgen-induced alopecia is the most common Hair loss is a common skin disease characterized by hair loss, with an incidence rate of up to 70% and 40% in all men and women
At present, the most common type of hair loss clinically is androgen-induced alopecia, also known as seborrheic alopecia
What is distressing is that androgen-induced alopecia has become a chronic progressive disease, and there is no effective treatment method so far, which also makes patients bear a huge psychological burden
Gao Jianqing told China Science Daily that androgenetic alopecia is usually caused by vascular insufficiency or oxidative stress
In addition, excessive reactive oxygen species can also trigger the premature aging of dermal papilla cells, and subsequently inhibit the transformation of hair follicles from the resting phase to the growth phase through androgen signals and their receptors
It has been confirmed that the accumulation of excessive reactive oxygen species can prevent angiogenesis and increase vascular dysfunction.
Microneedle patch promotes hair regrowth
Microneedle patch promotes hair regrowth Studies have found that nanoparticles containing cerium oxide can mimic enzymes that remove active oxygen
Gao Jianqing said that as a powerful transdermal drug delivery system, the microneedle patch can deliver drugs directly to the epidermis and dermis through a safe channel, which is feasible in the treatment of hair loss
According to reports, the researchers used hyaluronic acid as the needle body matrix of the microneedle patch, loaded the needle body with cerium oxide nanoenzyme, and pierced the skin stratum corneum through the microneedle.
At present, there are mainly two anti-androgen-induced hair loss drugs, "minoxidil" and "finasteride" on the market.
In the experiment of androgenic mouse model, the research team tested minoxidil topical preparation and cerium oxide microneedle patch, and found that the cerium oxide microneedle patch can be as low as minoxidil at a lower dosing frequency.
The effect
.
Specifically, the microneedle patch was administered once every 3 days for a total of 5 administrations; minoxidil was administered once a day for a total of 13 administrations
.
The cerium oxide microneedle patch can induce hair regrowth faster and achieve a new hair quality equivalent to that of the minoxidil group
.
Subsequently, the researchers further confirmed that the cerium oxide microneedle patch can effectively remove active oxygen, shape a better microenvironment for hair regeneration, and better promote the regeneration of blood vessels around the hair follicle
.
Moreover, the microneedle patch has high safety, does not cause reversible damage to the skin, and does not damage the normal structure of the skin
.
Commercialization still faces challenges
Commercialization still faces challenges Gao Jianqing said that the invention of this innovative integrated drug delivery system can derive more products for the treatment of hair loss, which is expected to further industrialize and benefit patients with androgen-induced alopecia
.
However, the technology is still in the basic research stage, and there is still a long way to go before large-scale commercialization
.
"If the composite of ceria nanoenzyme and micro-needle patch is to be truly applied to the human body, it is necessary to pass various index evaluations and reviews to ensure the batch-to-batch stability of raw materials and composite micro-needles.
There are still many challenges in the process of transformation
.
" Gao Jianqing said
.
First of all, as a new form of compound administration, it needs to be supported at the regulatory level and must be strictly approved by the corresponding national review agency before it can be used on the human body
.
Secondly, the research is still in the stage of small-scale and mechanism exploration, and the research of large-scale products has not been completed.
There may be some technical problems such as scale-up production in the process of exploration
.
In terms of curative effect, the research performance on experimental animals cannot be completely equated with the human body.
For example, the performance in animals is good, but there may still be the risk of failure in humans
.
Gao Jianqing said that in the future, the team hopes to work with partner companies to make more in-depth efforts at the level of application transformation, conduct a larger amount of scientific research, and overcome the current challenges one by one
.
(Source: China Science News Li Huiyu)
Related paper information: http://doi.
org/10.
1021/acsnano.
1c05272
http://doi.
org/10.
1021/acsnano.
1c05272
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
